These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11237673)

  • 1. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma.
    Lui VW; He Y; Huang L
    Mol Ther; 2001 Feb; 3(2):169-77. PubMed ID: 11237673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.
    Wiechen K; Zimmer C; Dietel M
    Cancer Gene Ther; 1998; 5(1):45-51. PubMed ID: 9476966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines.
    Tekur S; Ho SM
    Mol Carcinog; 2002 Jan; 33(1):44-55. PubMed ID: 11807957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme.
    Yokoyama Y; Morishita S; Takahashi Y; Hashimoto M; Tamaya T
    Br J Cancer; 1997; 76(8):977-82. PubMed ID: 9376277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting.
    Juhl H; Downing SG; Wellstein A; Czubayko F
    J Biol Chem; 1997 Nov; 272(47):29482-6. PubMed ID: 9368008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene.
    Kao MC; Liu GY; Chuang TC; Lin YS; Wuu JA; Law SL
    Oncogene; 1998 Jan; 16(4):547-54. PubMed ID: 9484845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hammerhead ribozyme against human telomerase catalytic subunit (hTERT) induced apoptosis of liver cancer cells].
    Song DP; Lin JS; Fu GL; Sun XM; Kong XJ; Li PY; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):616-9. PubMed ID: 15504295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
    Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
    Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme.
    Luo X; Gong X; Tang CK
    Int J Cancer; 2003 May; 104(6):716-21. PubMed ID: 12640678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
    Qian S; Somlo G; Zhou B; Zhu L; Mi S; Mo X; Cheung EM; Qiu W; Lin RJ; Rossi J; Holtz M; Chu P; Yen Y
    Oligonucleotides; 2005; 15(1):1-11. PubMed ID: 15788896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of adenovirus for high level expression of small RNAs in mammalian cells. Application to a Bcl-2 ribozyme.
    Potter PM; McKenzie PP; Hussain N; Noonberg S; Morton CL; Harris LC
    Mol Biotechnol; 2000 Jun; 15(2):105-14. PubMed ID: 10949823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme.
    Bi F; Fan D; Hui H; Wang C; Zhang X
    Cancer Gene Ther; 2001 Nov; 8(11):835-42. PubMed ID: 11773973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme.
    Chen S; Song CS; Lavrovsky Y; Bi B; Vellanoweth R; Chatterjee B; Roy AK
    Mol Endocrinol; 1998 Oct; 12(10):1558-66. PubMed ID: 9773979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity.
    Liang H; O'Reilly S; Liu Y; Abounader R; Laterra J; Maher VM; McCormick JJ
    Int J Oncol; 2004 May; 24(5):1057-67. PubMed ID: 15067326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
    Jones J; Lagasse LD; Karlan BY
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth.
    He P; Zhu D; Hu JJ; Peng J; Chen LS; Lu GX
    Mol Biol Rep; 2010 Mar; 37(3):1597-604. PubMed ID: 19444644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O; Hacker NF; Cho-Chung YS
    Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
    Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of kit expression in P815 mouse mastocytoma cells by a hammerhead ribozyme.
    Shelburne CP; Huff TF
    Clin Immunol; 1999 Oct; 93(1):46-58. PubMed ID: 10497010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.